Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Celiprolol pneumonitis

J N Lombard1, B Bonnotte, M Maynadie

  • 1Service de Pneumologie et de Réanimation Respiratoire, Centre Hospitalier Universitaire, Dijon, France.

The European Respiratory Journal
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).

European journal of cancer (Oxford, England : 1990)·2025
Same author

Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer.

Respiratory medicine and research·2024
Same author

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.

Thrombosis research·2024
Same author

[What about the new ACR/EULAR classification criteria for giant cell arteritis?]

La Revue de medecine interne·2023
Same author

La Revue de medecine interne·2023
Same author

[How to apply the EULAR and ACR recommendations for the diagnosis and treatment of giant cell arteritis?]

La Revue de medecine interne·2022
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Celiprolol, a beta-blocker, can cause hypersensitivity pneumonitis, a severe lung inflammation. This drug-induced lung disease is reversible upon discontinuation and may occur with other beta-blockers.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Toxicology

Background:

  • Beta-blockers are commonly prescribed cardiovascular drugs.
  • Hypersensitivity pneumonitis (HP) is an immune-mediated lung disease.
  • Drug-induced HP is a recognized but uncommon adverse effect.

Observation:

  • A patient developed severe alveolitis with compromised gas exchange during celiprolol treatment.
  • Rechallenge with celiprolol resulted in recurrent pneumonitis.
  • Elevated lymphocytes in bronchoalveolar lavage normalized after drug cessation.

Findings:

  • Celiprolol can induce hypersensitivity pneumonitis.
  • The condition is characterized by severe alveolitis and reversible gas exchange impairment.
  • Lymphocytic inflammation in bronchoalveolar lavage is a key feature.

Related Experiment Videos

Implications:

  • Clinicians should consider celiprolol as a potential cause of hypersensitivity pneumonitis.
  • Early recognition and drug withdrawal are crucial for reversibility.
  • This case highlights the potential for beta-blockers to cause drug-induced lung disease.